64 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
, as well as to fund the development of our deep clinical and preclinical pipeline. The progress made across our pipeline positions the Company for long … -term success and towards achieving our objective to become a fully integrated pharmaceutical company.”
First Quarter 2024 and Recent Highlights:
Phase
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
Cushing’s Syndrome Trial
Data from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be Presented, in Addition to New Long-Term Safety … program will be a poster showing long-term safety and efficacy updates from the Phase 2 ACROBAT Advance open-label extension study.
*Proposed
S-3ASR
h4in9 g3yn397g9m59
19 Mar 24
Automatic shelf registration
4:05pm
8-K
EX-99.2
abmlo2ee7zapm
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.2
jgch43zrg 0cto5f
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-99.1
bisepw 29
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
pybd666bs47a6h5oqrh
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
39bxp
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.1
ll45ih4x9
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.2
y47978u
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
1z7dxbfafss8lkbq1 pi
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-1.1
5wl6nwl2uh a9
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm